Sun Pharma’s GLP-1 Breakthrough: Affordable Weight-Loss and Diabetes Care Launches in India

In a landmark move for Indian healthcare, Sun Pharmaceutical Industries has officially launched its generic versions of the blockbuster drug semaglutide. Following the patent expiry of the innovator molecule (originally marketed by Novo Nordisk as Ozempic and Wegovy) on March 20, 2026, Sun Pharma has introduced two specialized brands designed to make this "miracle drug" accessible to the Indian masses. The launch is expected to disrupt the metabolic health market, where high costs have previously limited access to advanced GLP-1 therapies.